{"schema_version":"secwatch.filing_event.v1","accession":"0001649094-25-000073","form_type":"8-K","ticker":"PCVX","cik":"0001649094","company_name":"Vaxcyte, Inc.","filed_at":"2025-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.190976+00:00","generated_at":"2026-05-22T08:18:56.361888+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Vaxcyte Q1 net loss $140.7M; VAX-24 infant data positive, VAX-31 Phase 3 set for mid-2025","bullets":["Net loss $140.7M vs $95.0M YoY; cash, equivalents & investments $2.95B at March 31, 2025.","VAX-24 infant Phase 2 met non-inferiority criteria for 20 of 24 serotypes; robust OPA responses.","VAX-31 infant Phase 2 advanced to second stage; adult Phase 3 non-inferiority study to start mid-2025.","New third-generation PCV candidate VAX-XL announced to further expand serotype coverage.","Dr. Olivier Brandicourt (ex-Sanofi CEO) appointed to Board of Directors."],"urls":{"canonical":"https://secwatch.observer/filing/0001649094-25-000073","json":"https://secwatch.observer/filing/0001649094-25-000073.json","markdown":"https://secwatch.observer/filing/0001649094-25-000073.md","text":"https://secwatch.observer/filing/0001649094-25-000073.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649094/000164909425000073/0001649094-25-000073-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649094/000164909425000073/pcvx-20250507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T08:18:56.361888+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}